Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Brian Kaplan

Reproductive Endocrinology Glenview, IL Medical Doctor

NPI 1881737484 CMS profile 1282094

2555 Patriot Blvd Ste 100, Glenview, IL 60026

Open in the dashboard

General payments

$3,914

200 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Brian Kaplan of Glenview, IL is reported in the CMS Open Payments database as having received $3,914 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $359 16
2023 General $733 34
2022 General $655 35
2021 General $780 38
2020 General $487 26
2019 General $900 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Kaplan
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Brian Kaplan were reported at $0. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Brian Kaplan Reproductive Endocrinology median Middle half National median
2019 $900 $196 $77–$425 $163
2020 $487 $81 $35–$182 $114
2021 $780 $102 $43–$247 $132
2022 $655 $139 $62–$303 $149
2023 $733 $141 $65–$285 $160
2024 $359 $144 $65–$302 $164
2025 $0 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Ferring Pharmaceuticals Inc. $1,664 86 payments
  2. EMD Serono, Inc. $770 44 payments
  3. Organon LLC $655 34 payments
  4. Merck Sharp & Dohme Corporation $378 22 payments
  5. Galen US Inc $283 7 payments
  6. CooperSurgical, Inc. $78 2 payments
  7. Avion Pharmaceuticals $67 4 payments
  8. AbbVie, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,611 178 payments
  2. Education $304 22 payments
Products named General payments · program years 2019–2024
  1. MENOPUR $928 51 payments
  2. ENDOMETRIN $644 31 payments
  3. FOLLISTIM AQ Follitropin $570 27 payments
  4. PREGNYL $452 22 payments
  5. GANIRELIX ACETATE Ganirelix Acetate $409 19 payments
  6. FOLLISTIM AQ Womens Health $378 22 payments
  7. SYNERA $244 6 payments
  8. GANIRELIX $158 14 payments
  9. Gonal-f $141 12 payments
  10. Ganirelix Acetate Hormones $84 6 payments
  11. Other $520 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record